Paediatric chronic hepatitis C and the global elimination gap: burden and trends from 1990 to 2023 in the Global Burden of Disease Study 2023
Abstract
Background: Paediatric chronic hepatitis C (PCHC) is often asymptomatic and underdiagnosed, and its contemporary global burden remains incompletely characterised. We estimated global, national, and socioeconomic trends in PCHC using Global Burden of Disease (GBD) 2023 estimates, and hepatitis C virus (HCV)-related liver cancer as a limited Supplementary analysis. Methods: We analysed GBD 2023 estimates of prevalence, mortality, and disability-adjusted life years (DALYs) for PCHC in people younger than 20 years from 1990 to 2023. Results were summarised globally, across seven official GBD super-regions, and for 204 countries and territories using annual point estimates and supplied 95% uncertainty intervals. Because HCV-related liver cancer estimates were unavailable for children younger than 10 years, analyses of this endpoint were restricted to ages 10–19 years. Findings: Global PCHC prevalence was 0.380% (95% uncertainty interval [UI] 0.314–0.452) in 2023, representing a decline from 0.443% (0.376–0.514) in 1990, with an absolute change of −0.062 percentage points and a relative change of −14.1%. Mortality declined from 0.0890 (0.0504–0.1538) to 0.0595 (0.0303–0.1023) deaths per 100,000 population younger than 20 years, and the DALY rate declined from 7.49 (4.36–12.92) to 5.06 (2.62–8.40) per 100,000. The highest prevalences clustered in Central Asia, South-East Asia, and sub-Saharan Africa. Interpretation: The PCHC burden has declined globally, particularly mortality and DALYs, but prevalence has fallen only modestly. The continued high burden in Central Asia, South-East Asia, and sub-Saharan Africa, and marked country heterogeneity highlight the need to integrate antenatal screening, follow-up of perinatally exposed infants, and access to curative treatment for children aged 3 years or older into hepatitis elimination programmes in order to reach the 2030 elimination targets. Funding: National Institutes of Health.
Related
- Why Outcomes Diverge in Chronic Hepatitis B with Steatotic Liver Disease: Lessons from Within-Study Contrasts
- Global, regional, and national burden of chronic hepatitis C including cirrhosis from 1990 to 2021, alongside projections for the next 15 years.
- Histopathology Versus Imaging: A Comparative Study of Liver Biopsy, Ultrasonography, and Triphasic Computed Tomography in Paediatric Patients With Chronic Liver Disease.
- Superiority of magnetic resonance elastography and proton density fat fraction: an umbrella meta-analysis of non-invasive imaging for hepatic steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease and chronic hepatitis B.
- Complete remission of minimal change disease after antiviral monotherapy in a patient with immune-active chronic hepatitis B: A case report.
BibTeX
@article{hong2026paediatric,
title = {{Paediatric chronic hepatitis C and the global elimination gap: burden and trends from 1990 to 2023 in the Global Burden of Disease Study 2023}},
author = {Suk-Jin Hong and Xinlian Zhang and Farihah Malik and Lynette Goh Suk-Hui and Mortada H.F. El-Shabrawi and Mirta Ciocca and Giuseppe Indolfi and Winita Hardikar and Deirdre Kelly and Kathleen B. Schwarz and Phillipp Hartmann},
journal = {eClinicalMedicine},
year = {2026},
month = oct,
doi = {10.1016/j.eclinm.2026.104281},
url = {https://linkinghub.elsevier.com/retrieve/pii/S2589537026005341},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Paediatric chronic hepatitis C and the global elimination gap: burden and trends from 1990 to 2023 in the Global Burden of Disease Study 2023
AU - Suk-Jin Hong
AU - Xinlian Zhang
AU - Farihah Malik
AU - Lynette Goh Suk-Hui
AU - Mortada H.F. El-Shabrawi
AU - Mirta Ciocca
AU - Giuseppe Indolfi
AU - Winita Hardikar
AU - Deirdre Kelly
AU - Kathleen B. Schwarz
AU - Phillipp Hartmann
PY - 2026
DA - 2026/10/24
JO - eClinicalMedicine
DO - 10.1016/j.eclinm.2026.104281
UR - https://linkinghub.elsevier.com/retrieve/pii/S2589537026005341
AB - Background: Paediatric chronic hepatitis C (PCHC) is often asymptomatic and underdiagnosed, and its contemporary global burden remains incompletely characterised. We estimated global, national, and socioeconomic trends in PCHC using Global Burden of Disease (GBD) 2023 estimates, and hepatitis C virus (HCV)-related liver cancer as a limited Supplementary analysis. Methods: We analysed GBD 2023 estimates of prevalence, mortality, and disability-adjusted life years (DALYs) for PCHC in people younger than 20 years from 1990 to 2023. Results were summarised globally, across seven official GBD super-regions, and for 204 countries and territories using annual point estimates and supplied 95% uncertainty intervals. Because HCV-related liver cancer estimates were unavailable for children younger than 10 years, analyses of this endpoint were restricted to ages 10–19 years. Findings: Global PCHC prevalence was 0.380% (95% uncertainty interval [UI] 0.314–0.452) in 2023, representing a decline from 0.443% (0.376–0.514) in 1990, with an absolute change of −0.062 percentage points and a relative change of −14.1%. Mortality declined from 0.0890 (0.0504–0.1538) to 0.0595 (0.0303–0.1023) deaths per 100,000 population younger than 20 years, and the DALY rate declined from 7.49 (4.36–12.92) to 5.06 (2.62–8.40) per 100,000. The highest prevalences clustered in Central Asia, South-East Asia, and sub-Saharan Africa. Interpretation: The PCHC burden has declined globally, particularly mortality and DALYs, but prevalence has fallen only modestly. The continued high burden in Central Asia, South-East Asia, and sub-Saharan Africa, and marked country heterogeneity highlight the need to integrate antenatal screening, follow-up of perinatally exposed infants, and access to curative treatment for children aged 3 years or older into hepatitis elimination programmes in order to reach the 2030 elimination targets. Funding: National Institutes of Health.
SN - 2589-5370
ER -